Trial Profile
Anti-Osteoclast Therapy as Neoadjuvant in Treatment of Chondrosarcoma - Phase 1b Trial
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 16 Jan 2024
Price :
$35
*
At a glance
- Drugs Zoledronic acid (Primary)
- Indications Chondrosarcoma
- Focus Adverse reactions; Therapeutic Use
- 11 Jan 2024 Status changed from recruiting to active, no longer recruiting.
- 28 Jul 2023 Planned End Date changed from 1 Jul 2023 to 1 Jul 2024.
- 28 Jul 2023 Planned primary completion date changed from 1 Jul 2023 to 1 Jul 2024.